Skip to main content
Download PDF

Causal impact of gut microbiota and associated metabolites on pulmonary arterial hypertension: a bidirectional Mendelian randomization study

BMC Pulmonary Medicine volume 24, Article number: 185 (2024) Cite this article

Abstract

Background

Patients with pulmonary arterial hypertension (PAH) exhibit a distinct gut microbiota profile; however, the causal association between gut microbiota, associated metabolites, and PAH remains elusive. We aimed to investigate this causal association and to explore whether dietary patterns play a role in its regulation.

Methods

Summary statistics of gut microbiota, associated metabolites, diet, and PAH were obtained from genome-wide association studies. The inverse variance weighted method was primarily used to measure the causal effect, with sensitivity analyses using the weighted median, weighted mode, simple mode, MR pleiotropy residual sum and outlier (MR-PRESSO), and MR-Egger methods. A reverse Mendelian randomisation analysis was also performed.

Results

Alistipes (odds ratio [OR] = 2.269, 95% confidence interval [CI] 1.100–4.679, P = 0.027) and Victivallis (OR = 1.558, 95% CI 1.019–2.380, P = 0.040) were associated with an increased risk of PAH, while Coprobacter (OR = 0.585, 95% CI 0.358–0.956, P = 0.032), Erysipelotrichaceae (UCG003) (OR = 0.494, 95% CI 0.245–0.996, P = 0.049), Lachnospiraceae (UCG008) (OR = 0.596, 95% CI 0.367–0.968, P = 0.036), and Ruminococcaceae (UCG005) (OR = 0.472, 95% CI 0.231–0.962, P = 0.039) protected against PAH. No associations were observed between PAH and gut microbiota-derived metabolites (trimethylamine N-oxide [TMAO] and its precursors betaine, carnitine, and choline), short-chain fatty acids (SCFAs), or diet. Although inverse variance-weighted analysis demonstrated that elevated choline levels were correlated with an increased risk of PAH, the results were not consistent with the sensitivity analysis. Therefore, the association was considered insignificant. Reverse Mendelian randomisation analysis demonstrated that PAH had no causal impact on gut microbiota-derived metabolites but could contribute to increased the levels of Butyricicoccus and Holdemania, while decreasing the levels of Clostridium innocuum, Defluviitaleaceae UCG011, Eisenbergiella, and Ruminiclostridium 5.

Conclusions

Gut microbiota were discovered suggestive evidence of the impacts of genetically predicted abundancy of certain microbial genera on PAH. Results of our study point that the production of SCFAs or TMAO does not mediate this association, which remains to be explained mechanistically.

Peer Review reports

Research in context

Evidence before this study

Previous studies have reported that patients with pulmonary arterial hypertension (PAH) exhibit a distinct gut microbiota profile, characterised by a reduction in the number of bacteria that produce short-chain fatty acids. Moreover, gut microbiota-derived metabolites, such as trimethylamine N-oxide, are elevated in patients with PAH and are associated with an unfavourable prognosis. However, the causal association between gut microbiota, associated metabolites, and PAH remains elusive.

Added value of this study

In this study, we aimed to investigate the causal relationship between gut microbiota, associated metabolites, and PAH and explore whether dietary patterns mediate this causal relationship using bidirectional Mendelian randomisation. The gut microbiota exhibits a potential protective effect against PAH, including Coprobacter, Erysipelotrichaceae (UCG003), Lachnospiraceae (UCG008), and Ruminococcaceae (UCG005). In contrast, Alistipes and Victivallis were associated with an increased risk of PAH. Furthermore, PAH also had suggestive effects on gut microbiota, including the elevation of Butyricicoccus and Holdemania and the reduction of Clostridium innocuum, Defluviitaleaceae UCG011, Eisenbergiella, and Ruminiclostridium 5. However, we did not observe a significant causal association between gut microbiota-dependent metabolites (trimethylamine N-oxide and its precursors), short-chain fatty acids, and PAH. Moreover, dietary patterns were not associated with PAH, suggesting that dietary patterns do not mediate the association between gut microbiota, associated metabolites, and PAH.

Implications of the available evidence

Genetically predicted gut microbiota has a suggestive causal effect on PAH, and the underlying mechanism may be attributed to alternative factors rather than the production of short-chain fatty acids and trimethylamine N-oxide. Further studies are warranted to elucidate the mechanisms underlying the relationship between gut microbiota and PAH.

Background

Pulmonary arterial hypertension (PAH) is characterised by the chronic elevation of pulmonary arterial pressure and remodelling of the pulmonary arteries, which can ultimately lead to heart failure and mortality [1]. Several factors contributing to the development of PAH have been identified, including genetic susceptibility, underlying cardiovascular diseases, toxic exposure, and inflammation [2]. Recent studies have revealed that gut microbiota and its associated metabolites play vital roles in the pathogenesis of PAH. The gut microbiota, together with its metabolites, participates in various metabolic processes, such as cholesterol accumulation, impaired glucose tolerance, and elevated inflammatory responses, all of which promote the progression of PAH [3, 4]. Previous studies reported that patients with PAH exhibit a distinct gut microbiota profile characterised by a reduction in bacteria that produce short-chain fatty acids (SCFAs), including Coprococcus, Lachnospiraceae, Eubacterium, and Clostridia [5]. Moreover, gut microbiota-derived metabolites, namely trimethylamine N-oxide (TMAO) and its precursors choline, betaine, and carnitine, are elevated in patients with PAH and are associated with an unfavourable prognosis [3,4,5].

Despite the growing body of research examining the association between gut microbiota, its derived metabolites, and PAH, the majority of these studies have been cross-sectional or observational in nature and were unable to establish a causal relationship between PAH and gut microbiota. Additionally, the observed association between gut microbiota and PAH in cross-sectional or observational studies might be affected by reverse causation bias or confounders, such as dietary patterns. Moreover, the small sample sizes of these studies limit the robustness and generalisability of the conclusions. Therefore, the causality between gut microbiota, associated metabolites, and PAH warrants further investigation.

Mendelian randomisation, which introduces genetic variants as instrumental variables, is widely used to identify the causal effects of exposure on particular outcomes. Compared to traditional observational or cross-sectional studies, Mendelian randomisation is less prone to confounding because genetic alleles are randomly allocated during gametogenesis. Furthermore, Mendelian randomisation can mitigate the potential for reverse causation bias, as genotypes are determined prior to disease onset [6]. Therefore, in this study, we aimed to use a two-sample Mendelian randomisation method to investigate the causal relationship between gut microbiota, associated metabolites, and PAH. We also explored whether dietary patterns mediated this causal relationship.

Methods

Study design

Single nucleotide polymorphisms (SNPs) used as instrumental variables should satisfy three assumptions: (i) the SNP correlates with exposure, namely gut microbiota, associated metabolites, and dietary patterns; (ii) the SNP does not correlate with confounding variables that could affect the association between exposure and PAH; and (iii) the SNP correlates with PAH exclusively through exposure rather than through other pathways. We explored the causal relationship between gut microbiota, associated metabolites, and PAH. We also evaluated whether dietary patterns mediated this association (Fig. 1).

Fig. 1
figure 1

Study overview. Legend: SCFA, short chain fatty acids; TMAO, trimethylamine N-oxide. The figure illustrates the design of the study. In this study, we aim to investigate the causal relationship between gut microbiota, associated metabolites and PAH, and explore whether dietary patterns mediate the above causal relationship using two-sample Mendelian randomization

Full size image

Data sources

We obtained the genetic variants for gut microbiota from the current largest genome-wide meta-analysis of gut microbiota composition, which was conducted by the MiBioGen consortium (https://mibiogen.gcc.rug.nl/) [7]. The study included 18,340 participants from 24 cohorts, most of whom were European [7]. The V1–V2, V3, and V4 variable regions of the 16S rRNA gene were used to identify microbial composition. The lowest taxonomic level in this study was at the genus level. This study encompassed 131 genera, each exhibiting an average abundance exceeding 1%. Of these, 12 genera were unknown. Consequently, this study included 119 genera.

To reduce the bias introduced by the study population, we limited the analytical studies to European populations. We searched for genetic variants of gut microbiota-derived metabolites, including TMAO, choline, betaine, carnitine, SCFAs, dietary patterns, and PAH, using genome-wide association studies (GWAS). The GWAS used to extract the summary-level data are detailed in Table 1 and Supplementary Table S1. This study was approved by ethic committee of Fuwai Hospital, Beijing, China.

Table 1 Causal effect of gut microbiota and dependent metabolite on pulmonary arterial hypertension
Full size table

SNP selection

The SNPs for instrumental variables were selected as follows: (i) the SNP correlated with gut microbiota at locus-wide significance with P < 5 × 10−5 [8, 9]; (ii) to ensure the independence of instrumental variables, the selected SNPs were clumped using 1000 Genomes Project European sample data as a reference, employing a clumping window of 10,000 kb and a linkage disequilibrium R2 threshold of < 0.001; (iii) the instrument strength was evaluated using the F-statistic, and the variance was quantified using r2. SNPs with an F statistic of < 10 were excluded because of weak instrument bias [10].

Data analysis

The inverse variance weighted (IVW) method was primarily used to measure the causal effect of gut microbiota, associated metabolites, and dietary patterns on PAH, which demonstrates a combined causal estimate from each SNP [11]. The weighted median, weighted mode, simple mode, MR-PRESSO, and MR-Egger analyses were performed to examine the validity of the results. A stable causal association can only be established when the sensitivity analysis yields results consistent with those of the IVW method [12]. The weighted median method can provide unbiased estimates of causal associations when half of the instrumental variables are invalid. The MR-PRESSO approach was applied to detect SNP outliers and to provide estimates after removing outliers [13]. Leave-one-out analysis was used to evaluate whether a variant drove the correlation between exposure and outcome by removing a single SNP each time [12, 14]. The MR-Egger regression was applied to detect pleiotropy, and an intercept that was significantly distinct from zero indicated the existence of pleiotropy [15]. The slope of the MR-Egger regression provided causal estimates after the pleiotropy correlation. The Cochrane Q statistic was used to evaluate heterogeneity [12]. Given the multiple tests used in this study, the Bonferroni-corrected threshold of statistical significance was P < 0.0004 (0.05/131). A P value between 0.0004 and 0.05 was regarded as a suggestive association. All statistical analyses were performed using the R software (version 4.0.5; R Foundation for Statistical Computing, Vienna, Austria). MR analyses were performed using TwosampleMR [16] and MR-PRESSO [13] packages.

Results

Figure 2 demonstrates the study design. The features of the selected SNPs in gut microbiota and its associated metabolites are shown in Supplementary Table S1. A total of 5394 SNPs were selected as instrumental variants for 119 bacterial genera; 311 SNPs for SCFAs, including acetate, indolepropionate, and 3-hydroxybutyrate; and 490 SNPs for TMAO, along with its precursors (Supplementary Table S2).

Fig. 2
figure 2

Flow Chart of the Study Design. Legend: SNP, single nucleotide polymorphisms

Full size image

Causal effect of gut microbiota on PAH

According to the Mendelian randomisation analysis results, genetically predicted Alistipes (OR [odds ratio]= 2.269, 95% CI [confidence interval] 1.100–4.679, P = 0.027) and Victivallis (OR = 1.558, 95% CI 1.019–2.380, P = 0.040) were associated with an increased risk of PAH, while Coprobacter (OR = 0.585, 95% CI 0.358–0.956, P = 0.032), Erysipelotrichaceae (UCG003) (OR = 0.494, 95% CI 0.245–0.996, P = 0.049), Lachnospiraceae (UCG008) (OR = 0.596, 95% CI 0.367–0.968, P = 0.036), and Ruminococcaceae (UCG005) (OR = 0.472, 95% CI 0.231–0.962, P = 0.039) could causally protect against PAH (Table 1, Supplementary Table S3, Figs. 3-4). The leave-one-out plots did not suggest that any of the IVW estimates were significantly affected by individual outlier SNPs (Fig. 5). Funnel plots demonstrated no asymmetry in the SNP estimates throughout the range of precision (Supplementary Fig. S1). Sensitivity analysis using the weighted median, weighted mode, simple mode, MR-PRESSO, and MR-Egger regression methods yielded similar results (Table 1, Supplementary Table S3). Cochrane’s IVW Q test showed no heterogeneity in these instrumental variables (all P > 0.05, Table 2 and Supplementary Table S4). The MR-Egger regression intercept demonstrated no significant directional pleiotropy, as all 95% CIs of the intercepts included zero (all P > 0.05) (Table 2 and Supplementary Table S5). The MR-PRESSO analysis did not identify any potential outlier SNPs in these bacteria, indicating no horizontal pleiotropy in the causal relationship between these bacteria and PAH (Supplementary Table S6).

Fig. 3
figure 3

Scatter plot of MR results of bacteria on pulmonary arterial hypertension. Legend: Each dot represents the size of the SNP exposure impact in standard deviation units with the accompanying standard error. The lines represent the effect size calculated by the mendelian randomization method with the corresponding color. MR, Mendelian randomization; SNP, single nucleotide polymorphisms

Full size image
Fig. 4
figure 4

Forest plot of MR results of bacteria on pulmonary arterial hypertension. Legend: Each line represents the effect size of the corresponding SNP with the accompanying standard error. The red lines represent the average effect size of all SNP calculated by the MR egger and inverse variance weighted method respectively. MR, Mendelian randomization; SNP, single nucleotide polymorphisms

Full size image
Fig. 5
figure 5

The leave-one-out analysis of MR results of bacteria on pulmonary arterial hypertension. Legend: The leave-one-out analysis removes a single SNP each time and calculates the meta-analysis effect of the remaining SNPs to observe whether the results change after removing each SNP, and if a SNP is removed, the results change greatly, indicating that the presence of the SNP has a great impact on the results. In this study, after removing a single SNP each time, the overall error bars did not change much, indicating that the results were reliable and not affected by heterogeneity. MR, Mendelian randomization; SNP, single nucleotide polymorphisms

Full size image
Table 2 The heterogeneity and horizontal pleiotropy for the causal effect of gut microbiota, its metabolites and dietary patterns on pulmonary arterial hypertension
Full size table

Causal effects of gut microbiota-derived metabolites and dietary parameters on PAH

Genetically predicted TMAO and its precursors, including betaine and carnitine, were not causally associated with PAH (all P > 0.05). Sensitivity analysis demonstrated consistent results (Table 1 and Supplementary Table S2). However, IVW demonstrated that elevated choline was suggestively correlated with an increased risk of PAH. Given the inconsistent outcomes of the sensitivity analysis, this association was considered insignificant. Both the MR-Egger regression and the IVW method demonstrated no heterogeneity in the metabolite SNPs (Table 2 and Supplementary Table S3). The MR-Egger regression tests and MR-PRESSO demonstrated that the results were not affected by pleiotropy (Table 2 and Supplementary Table S5 and Table S6).

IVW and sensitivity analyses indicated that SCFAs, including acetate, indolepropionate, and 3-hydroxybutyrate, were not associated with an increased risk of PAH (all P > 0.05, Table 1 and Supplementary Table S2). The results were not influenced by heterogeneity or pleiotropy (Supplementary Table S3–S5).

Genetically predicted dietary patterns, including alcohol use, fresh fruit intake, coffee intake, beef intake, and oily fish intake, were not causally associated with PAH (Supplementary Table S1–6). Therefore, dietary patterns did not mediate the association between gut microbiota and PAH (Supplementary Table S7).

Causal effects of PAH on gut microbiota and associated metabolites

Sixty SNPs with an F-statistic of > 10 were selected as instrumental variables for PAH, as detailed in Supplementary Table S8. Reverse Mendelian randomisation analysis demonstrated that PAH had no causal effect on gut microbiota-derived metabolites. However, PAH contributed to increased levels of Butyricicoccus and Holdemania and decreased levels of Clostridium (innocuum group), Defluviitaleaceae (UCG011), Eisenbergiella, and Ruminiclostridium 5 (Table 3 and Supplementary Table S9). No significant heterogeneity was observed in the selected instrumental variables, given that all the P values of the Cochrane IVW Q statistic were over 0.05 (Table 4 and Supplementary Table S10). The intercepts of the MR-Egger regression (Table 4 and Supplementary Table S11) and MR-PRESSO (Supplementary Table S12) analyses showed no significant horizontal pleiotropy among the causal effects of PAH on these bacteria.

Table 3 Causal effect of pulmonary arterial hypertension on gut microbiota and dependent metabolite
Full size table
Table 4 The heterogeneity and horizontal pleiotropy for the causal effect of pulmonary arterial hypertension on gut microbiota and its metabolites
Full size table

Discussion

The current study revealed the intricate interactions between gut microbiota and PAH, contributing to the burgeoning evidence of the influence of the microbiome on cardiovascular pathologies. Our study underscores the potential protective role of specific bacterial genera against PAH, including Coprobacter, Erysipelotrichaceae (UCG003), Lachnospiraceae (UCG008), and Ruminococcaceae (UCG005). In contrast, genera such as Alistipes and Victivallis emerged as potential risk factors, suggesting their contributory roles in PAH pathogenesis. Notably, our findings did not indicate significant mediation by dietary patterns in the microbiota–PAH axis, nor did we observe a causal association between gut microbiota-dependent metabolites and PAH.

The pivotal function of the gut microbiota in maintaining host homeostasis is well documented, with roles in nutrient metabolism, vitamin and hormone synthesis, immune system shaping, and resistance to pathogen colonisation [17]. Dysbiosis has been implicated in various conditions, including diabetes, coronary artery disease, heart failure, and hypertension [18]. Moreover, perturbations in the gut microbial composition have been documented in PH, which is characterised by reduced levels of beneficial bacteria [5], suggesting a possible association with PAH.

Studies have revealed that Lachnospiraceae and Ruminococcaceae, which are predominant in healthy individuals, are integral to gut integrity and metabolic processes [19]. Their associations with cardiovascular health indicators, such as arterial stiffness [20] and heart rate variability [21] further suggest that these bacteria contribute to cardiovascular homeostasis. A decline in the abundance of these genera in coronary artery disease [22], chronic heart failure [23], and HIV [24] highlights their beneficial roles.

Concurrently, an increase in Alistipes is associated with a higher risk of PAH. Alistipes, a potential pathogen, is associated with colorectal cancer [25], depression [25], diabetic nephropathy [26], and inflammation [25]. Its influence on hypertension pathogenesis is suggested by its positive correlation with systolic blood pressure in hypertensive individuals [27]. Similarly, the involvement of Victivallis, a strictly anaerobic bacterium, in the risk of PAH points to metabolic interplay, although the literature on its role is scant, warranting further investigation.

This study explored the controversial relationships between TMAO, its precursors, and PAH. Although some studies have indicated a correlation between elevated TMAO levels and adverse cardiovascular outcomes [28] [29], our MR analysis did not confirm a causal association. This is consistent with other MR studies that have questioned the causality of TMAO in cardiometabolic diseases [30, 31]. The inconclusive nature of the role of TMAO in PAH, coupled with the mixed prognostic implications [32, 33], indicates that observational associations may be confounded, highlighting the need for more detailed investigations.

However, the role of SCFAs in the development of PAH remains unclear. Despite their well-recognised systemic effects [34, 35], our findings do not support a direct causal relationship with PAH, pointing to a gap that future research should address.

The methodological strength of this study lies in the systematic evaluation of causal relationships using MR analysis, which is supported by extensive summary-level microbiota data. This approach mitigated reverse causation and confounding biases. Additionally, we investigated potential dietary confounders and validated our findings using multiple MR methods to ensure robustness.

However, this study had some limitations. Firstly, we selected SNPs for metabolites and bacteria at a suggestive locus-wide significance threshold of P < 5 × 10−5 [36], and our results might have been influenced by weak instrument bias. We performed a sensitivity analysis at the study-wide significance level of P < 5 × 10−8 and found that no SNP remained for metabolites and bacteria. Secondly, in the analysis of microbiota influences on PAH, MR only examines the impact of genetic factors that predispose individuals to specific abundances of particular microbial genera and how these genetic components influence the development of PAH. However, the impact of the environment and acquired risk factors on the causal association between bacteria and PAH could not be evaluated, which might contribute to the development of PAH. Thirdly, PAH may exhibit an association with specific microbial ‘types’ rather than taxonomic genera, and alpha diversity may also connect with PAH [37, 38]. Unfortunately, owing to the limitations of the MR method employed in our study, we were unable to evaluate the association between permatypes or enterotypes and the alpha diversity of microbiomes with PAH. We aim to investigate these issues in future studies. Fourthly, different ethnicities with PAH may have hereditary discrepancies. The current Mendelian randomisation analysis is primarily based on the European population, which limits the generalisability of the findings to other ethnic populations. However, limiting the European population may reduce the bias introduced by population stratification. Fifthly, this study explored the association between PAH and gut microbiota at the genus level. However, different species in the same genus may have discrepancies in their effects on metabolism and health, varying in the host and exposed environment. Some species may be protective, whereas others may exert detrimental effects on health. Studies at the species level can shed light on the precise causal associations between bacteria and diseases, along with the underlying pathological mechanisms. However, in the MiBioGen database, the lowest available level of bacteria was the genus level due to the limitations of 16S sequencing. Whole-genome shotgun metagenomics can address this limitation and provide insights into species-level resolution, which should be considered in future studies.

Conclusion

Genetically predicted gut microbiota has a suggestive causal effect on PAH, and the underlying mechanism may be attributed to alternative mechanisms rather than the production of SCFAs and TMAO.

Availability of data and material

All data are publicly available. Detailed information for these datasets is summarized in Table S 1 .

Abbreviations

SNP:

Single-nucleotide polymorphism

OR:

Odds ratio

CI:

Confidence interval

TMAO:

Trimethylamine N-oxide

PAH:

Pulmonary arterial hypertension

IVW:

Inverse variance weighted

SCFA:

Short-chain fatty acid

References

  1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–731.

    Article  CAS  PubMed  Google Scholar 

  2. Yang Y, Lin F, Xiao Z, Sun B, Wei Z, Liu B, et al. Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: an update. Biomed Pharmacother. 2020;129:110355.

    Article  CAS  PubMed  Google Scholar 

  3. Huang Y, Lin F, Tang R, Bao C, Zhou Q, Ye K, et al. Gut microbial metabolite trimethylamine N-oxide aggravates pulmonary hypertension. Am J Respir Cell Mol Biol. 2022;66(4):452–60.

    Article  CAS  PubMed  Google Scholar 

  4. Chen YH, Yuan W, Meng LK, Zhong JC, Liu XY. The role and mechanism of gut microbiota in pulmonary arterial hypertension. Nutrients. 2022;14(20).

  5. Kim S, Rigatto K, Gazzana MB, Knorst MM, Richards EM, Pepine CJ, et al. Altered gut microbiome profile in patients with pulmonary arterial hypertension. Hypertension. 2020;75(4):1063–71.

    Article  CAS  PubMed  Google Scholar 

  6. Tan J-S, Liu N-N, Guo T-T, Hu S, Hua L. Genetically predicted obesity and risk of deep vein thrombosis. Thromb Res. 2021;207:16–24.

    Article  CAS  PubMed  Google Scholar 

  7. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A, et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021;53(2):156–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51(4):600–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Li P, Wang H, Guo L, Gou X, Chen G, Lin D, et al. Association between gut microbiota and preeclampsia-eclampsia: a two-sample Mendelian randomization study. BMC Med. 2022;20(1):443.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Staiger D, Stock JH. Instrumental variables with weak instruments. Econometrica. 1997;65(3):557–86.

    Article  Google Scholar 

  11. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2016;35(11):1880–906.

    Article  PubMed  Google Scholar 

  12. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658–65.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol. 2014;43(3):922–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol. 2015;44(2):512–25.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hemani G, Tilling K, Davey SG. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Floch MH. Intestinal microecology in health and wellness. J Clin Gastroenterol. 2011;45(Suppl):S108-SS10.

    Article  PubMed  Google Scholar 

  18. Peng J, Xiao X, Hu M, Zhang X. Interaction between gut microbiome and cardiovascular disease. Life Sci. 2018;214:153–7.

    Article  CAS  PubMed  Google Scholar 

  19. Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol. 2019;17(8):497–511.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Menni C, Lin C, Cecelja M, Mangino M, Matey-Hernandez ML, Keehn L, et al. Gut microbial diversity is associated with lower arterial stiffness in women. Eur Heart J. 2018;39(25):2390–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tsubokawa M, Nishimura M, Mikami T, Ishida M, Hisada T, Tamada Y. Association of gut Microbial Genera with heart rate variability in the general Japanese population: the Iwaki cross-sectional research study. Metabolites. 2022;12(8).

  22. Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, et al. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. 2019;7(1):68.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Zhang Z, Cai B, Sun Y, Deng H, Wang H, Qiao Z. Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure. Front Cardiovasc Med. 2022;9:1076806.

    Article  CAS  PubMed  Google Scholar 

  24. Vujkovic-Cvijin I, Sortino O, Verheij E, Sklar J, Wit FW, Kootstra NA, et al. HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases. Nat Commun. 2020;11(1):2448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The genus Alistipes: gut Bacteria with emerging implications to inflammation, Cancer, and mental health. Front Immunol. 2020;11:906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Chen W, Zhang M, Guo Y, Wang Z, Liu Q, Yan R, et al. The profile and function of gut microbiota in diabetic nephropathy. Diabetes Metab Syndr Obes. 2021;14:4283–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kim S, Goel R, Kumar A, Qi Y, Lobaton G, Hosaka K, et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci (Lond). 2018;132(6):701–18.

    Article  CAS  PubMed  Google Scholar 

  28. Li J, Li Y, Ivey KL, Wang DD, Wilkinson JE, Franke A, et al. Interplay between diet and gut microbiome, and circulating concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men. Gut. 2022;71(4):724–33.

    Article  CAS  PubMed  Google Scholar 

  29. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and Meta-analysis of prospective studies. J Am Heart Assoc. 2017;6(7).

  30. Jia J, Dou P, Gao M, Kong X, Li C, Liu Z, et al. Assessment of causal direction between gut microbiota-dependent metabolites and Cardiometabolic health: a bidirectional Mendelian randomization analysis. Diabetes. 2019;68(9):1747–55.

    Article  CAS  PubMed  Google Scholar 

  31. Gagnon E, Mitchell PL, Manikpurage HD, Abner E, Taba N, Esko T, et al. Impact of the gut microbiota and associated metabolites on cardiometabolic traits, chronic diseases and human longevity: a Mendelian randomization study. J Transl Med. 2023;21(1):60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Yang Y, Zeng Q, Gao J, Yang B, Zhou J, Li K, et al. High-circulating gut microbiota-dependent metabolite trimethylamine N-oxide is associated with poor prognosis in pulmonary arterial hypertension. Eur Heart J Open. 2022;2(5):oeac021.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Videja M, Vilskersts R, Korzh S, Cirule H, Sevostjanovs E, Dambrova M, et al. Microbiota-derived metabolite trimethylamine N-oxide protects mitochondrial energy metabolism and cardiac functionality in a rat model of right ventricle heart failure. Front Cell Dev Biol. 2020;8:622741.

    Article  PubMed  Google Scholar 

  34. Ratajczak W, Rył A, Mizerski A, Walczakiewicz K, Sipak O, Laszczyńska M. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim Pol. 2019;66(1).

  35. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. Chapter three - the role of short-chain fatty acids in health and disease. In: Alt FW, editor. Advances in immunology. 121: Academic Press; 2014. p. 91–119.

    Google Scholar 

  36. Luo Q, Hu Y, Chen X, Luo Y, Chen J, Wang H. Effects of gut microbiota and metabolites on heart failure and its risk factors: a two-sample Mendelian randomization study. Front Nutr. 2022;9:899746.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Christensen L, Roager HM, Astrup A, Hjorth MF. Microbial enterotypes in personalized nutrition and obesity management. Am J Clin Nutr. 2018;108(4):645–51.

    Article  PubMed  Google Scholar 

  38. Klimenko NS, Tyakht AV, Popenko AS, Vasiliev AS, Altukhov IA, Ischenko DS, et al. Microbiome responses to an uncontrolled short-term diet intervention in the frame of the citizen science project. Nutrients. 2018;10(5).

Download references

Acknowledgements

Not applicable.

Funding

This research article was supported by Beijing Municipal Science and Technology Project [Grant No.Z181100001718200]; Beijing Municipal Natural Science Foundation [Grant No. 7202168]; National Clinical Medical Research Center for Cardiovascular Diseases (NCRC2020015) and High-Level Hospital Clinical Research Funding (2022-GSP-GG-26); Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences [Grant No. 2023-I2M-C&T-B-063]; National High Level Hospital Clinical Research Funding [Grant No.2022-GSP-GG-35], and Artificial Intelligence and Information Technology Application Fund of Fuwai Hospital, Chinese Academy of Medical Sciences [2022-AI01], Young Scientist Fund of Sichuan Provincial People’s Hospital [2023QN02]. Jing Xu was supported by the China Scholarship Council (No. 202306210349). The fundings were made to our institution and the funding had no relationship with the design, analysis, and writing of the current study.

Author information

Author notes

  1. Xin Li, Jiang-Shan Tan and Jing Xu contributed equally to this work and shared the first authorship.

Authors and Affiliations

  1. Center for Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 Beilishi Rd, Xicheng District, Beijing, 10003, China

    Xin Li, Zhihui Zhao, Qing Zhao, Yi Zhang, Anqi Duan, Zhihua Huang, Sicheng Zhang, Luyang Gao, Tao Yang, Qi Jin, Qin Luo & Zhihong Liu

  2. Emergency and Critical Care Center, Fuwai Hospital, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Jiang-Shan Tan & Yanmin Yang

  3. State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Jing Xu & Yue Jin Yang

  4. Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    Jing Xu

  5. Department of ICU, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China

    Yi Zhang

  6. University of Electronic Science and Technology of China, Chengdu, China

    Yi Zhang

  7. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China

    Qi Jin

Authors
  1. Xin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiang-Shan Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhihui Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anqi Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhihua Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sicheng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Luyang Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yue Jin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tao Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Qi Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Qin Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yanmin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Zhihong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: X.L., JS.T. and J.X.; Methodology: X.L. and JS.T. and J.X.; Formal analysis and investigation: YM.Y.,YJ.Y.,Y.Z., ZH.Z., Q.Z., Q.L. and ZH.H.; Data curation: YM.Y.,YJ.Y.ZH.H, AQ.D, LY.G. and SC.Z.; Writing-original draft preparation: X.L., JS.T. and J.X.; Writing-review and editing: X.L., Y.Z., ZH.Z., AQ.D. Q.Z., Q.L.,Q.J., T.Y. and ZH.H.; Visualization, ZH.H. SC.Z, and LY.G.; Funding acquisition: ZH.L., Q.L. and ZH.Z.; Supervision: ZH.L.,YM.Y.,YJ.Y. and ZH.Z.

Corresponding authors

Correspondence to Qin Luo, Yanmin Yang or Zhihong Liu.

Ethics declarations

Ethics approval and consent to participate

This study was approved by ethic committee of Fuwai Hospital, Beijing, China (Approval NO: 2022–1739).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, X., Tan, JS., Xu, J. et al. Causal impact of gut microbiota and associated metabolites on pulmonary arterial hypertension: a bidirectional Mendelian randomization study. BMC Pulm Med 24, 185 (2024). https://doi.org/10.1186/s12890-024-03008-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-024-03008-7

Keywords

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us